Suppression of the cell-mediated immune response by a Fas-immunoglobulin fusion protein

Transplantation

Volumn 81, Issue 7, 2006, Pages 1041-1048

  Shen, Yingnian ^a   Young, Barbara ^b   Lipman, Mark L ^c,d  

^a GLAXOSMITHKLINE   (United States)

^b ST MARY S HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Apoptosis; Fas; Fas ligand; Fusion protein; Immunosuppression

Indexed keywords

FAS ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN G2A; IMMUNOSUPPRESSIVE AGENT;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; HALF LIFE TIME; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; LYMPHOID TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

ANIMALS; APOPTOSIS; FAS LIGAND PROTEIN; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTORS;

EID: 33646374671     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000164289.18470.28     Document Type: Article

References (36)

1. Soulillou JP, Cantarovitch D, Le Mauff B. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175.
2. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193.
3. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161.
4. Suda T, Okazaki T, Naito Y, et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995; 154: 3806.
5. Anel A, Buferne M, Boyer C, et al. T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporine A. Eur J Immunol 1994; 24: 2469.
6. Alderson MR, Tough TW, Davis-Smith T, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995; 181: 71.
7. Zheng XX, Steele AW, Hancock WW, et al. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. J Immunol 1999; 163: 4041.
8. Kunzendorf U, Pohl T, Bulfone-Paus S, et al. Suppression of cell-mediated and humoral immune responses by an interleukin-2-immunoglobulin fusion protein in mice. J Clin Invest 1996; 97: 1204.
9. Steurer W, Nickerson PW, Steele AW, et al. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. J Immunol 1995; 155: 1165.
10. Zheng XX, Steele AW, Nickerson PW, et al. Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol 1995; 154:5590.
11. Lynch DH, Alderson MR, Ramsdell F. Immunoregulatory effects on Fas-mediated signalling. J Cell Biochem 1996; 60: 39.
12. Brown PS, Parenteau GL, Kirbas FM, et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Prac Natl Acad Sci USA 1990; 88: 2663.
13. Ravetch JV, Anderson CL. Fc gamma R family: proteins, transcripts, and genes. In: Metzler H, ed. Fc receptors and the action of antibodies. Washington, American Society for Microbiology, 1991: 211.
14. Bogers WMJM, Lang F, Parker KE, et al. Rat interleukin-2 immunoglobulin M fusion proteins are cytotoxic in vitro for cells expressing the IL-2 receptor and can abolish cell-mediated immunity in vivo. Transplantation 1994; 58: 932.
15. Kim YS, Maslinski W, Zheng XX, et al. Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fcγ2a protein blocks delayed-type hypersensitivity. J Immunol 1998; 160: 5742.
16. Pearson TC, Alexander DZ, Winn KJ, et al. Transplantation tolerance induced by CTLA4-Ig. Transplantation 1994; 57: 1701.
17. Tarumi K, Murakami M, Yagihashi A, et al. CTLA4-IgG treatment induces long-term acceptance of rat small bowel allografts. Transplantation 1999; 67: 520.
18. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907.
19. Liles WC, Kiener PA, Ledbetter JA, et al. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: Implications for the regulation of apoptosis in neutrophils. J Exp Med 1996; 184: 429.
20. Gersuk GM, Beckham C, Loken MR, et al. A role for tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Hematol 1998; 103: 176.
21. Schlapback R, Spanaus K-S, Malipiero U, et al. TGF-beta induces the expression of the FLICE-inhibitory protein and inhibits Fas-mediated apoptosis of microglia. Eur J Immunol 2000; 30: 3680.
22. Sandri M, Sandri C, Brun B, et al. Inhibition of FasL sustains phagocytic cells and delays myogenesis in regenerating muscle fibers. J Leukoc Biol 2001; 69: 482.
23. Matute-Bello G, Liles WC, Frevert CW, et al. Recombinant human Fas ligand induces alveolar epithelial cell apoptosis and lung injury in rabbits. Am J Physiol Lung Cell Mol Physiol 2001; 281: L328.
24. Lee J, Richburg JH, Younkin SC, et al. The Fas system is a key regulator of germ cell apoptosis in the testis. Endocrinology 1997; 138: 2081.
25. Guo MW, Xu JP, Mori E, et al. Expression of Fas ligand in murine ovary. Am J Reprod Immunol 1997; 37: 391.
26. Griffith TS, Yu X, Herndon JM, et al. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 1996; 5: 7.
27. Hunt JS, Vassmer D, Ferguson TA, et al. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol 1997; 158: 4122.
28. Suda T, Takahashi P, Golstein P, et al. Molecular cloning and expression of the Fas ligand, a novel member of tumor necrosis factor family. Cell 1993; 75: 1169.
29. Suda T, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 1994; 179: 873.
30. Larsen CP, Alexander DZ, Hendrix R, et al. Fas-mediated cytotoxicity; an immunoeffector or immunoregulatory pathway in T cell-mediated responses. Transplantation 1995; 60: 221.
31. Ozdemirli M, El-Khatib M, Foote LC, et al. Fas (CD95)/Fas ligand interactions regulate antigen-specific, major histocompatibility complex-restricted T/B cell proliferative responses. Eur J Immunol 1996; 26: 415.
32. Lu L, Qian S, Hershberger PA, et al. Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signal for T cell survival and proliferation. J Immunol 1997; 158: 5676.
33. Rouvier E, Luciani MF, Golstein P. Fas involvement in calcium-independent T cell-mediated cytotoxicity. J Exp Med 1993; 177: 195.
34. Sharma VK, Bologa RM, Li B. Molecular executors of cell death: differential intrarenal expression of Fas Ligand, Fas, granzyme B, and perform during acute and/or chronic rejection of human renal allografts. Transplantation 1996; 62: 695.
35. Seino K, Dayagaki N, Bashuda H, et al. Conribution of Fas ligand to cardiac allograt rjection. Int Immunol 1996; 8: 1347.
36. Djamali A, Odorico JS. Fas-mediated cytotoxicity is not required for rejection of murine non-vascularized heterotopic cardiac allografts. Transplantation 1998; 66: 1793.